Author Index

Bouchara, J.-P. 167
Brakhage, A.A. 149, 205
Crameri, R. 44
d’Enfert, C. 149
Ellis, M. 105
Esnault, K. 167
Espinel-Ingroff, A. 139
Horiuchi, H. 193
Jahn, B. 205
Jaton-Ogay, K. 182
Kappe, R. 88
Langfelder, K. 205
Laigè, J.P. 69
Mol, P.C. 149
Monod, M. 182
Naoe, S. 130
Rachel, R. 21
Reichard, U. 21, 182
Rimek, D. 88
Samson, R.A. 5
Sanchez, M. 167
Schaffner, A. 57
Schmidt, A. 1, 205
Schmidt, D.I. 1
Schneemann, M. 57
Shibuya, K. 130
Takagi, M. 193
Tronchin, G. 167
Wanner, G. 205
Weidner, G. 149
Yamaguchi, H. 130
Subject Index

Acquired immunodeficiency syndrome
aspergillosis manifestations and treatment 34
invasive aspergillosis, see Invasive aspergillosis

Aflatoxin-B, ingestion 24

Allergic bronchopulmonary aspergillosis
diagnosis 46, 51–53
incidence 46, 123
pathogenesis 25, 123, 131

Allergic disease, see also Allergic bronchopulmonary aspergillosis, Asthma, Extrinsic allergic alveolitis
antigen/allergen preparations from Aspergillus fumigatus
cloning 47–49
enzymes 72–74
identification 50–52, 71–76
polysaccharides 76, 77
recombinant proteins in diagnosis 52
standardization 45, 47, 69
variation sources of extracts 70, 71
Western blot analysis 71
cystic fibrosis patients 46
diagnosis 44–47

Amphotericin B, aspergillosis treatment
combination therapy
granulocyte-macrophage colony-stimulating factor 38, 120
intraconazole 115, 116
rifampicin 115, 116
dosage in invasive aspergillosis 38, 106, 111–114
formulations 109, 111–113
lipid product efficacy 112, 113
mechanisms of action 109
minimum inhibitory concentration 144, 145
response rates 111
toxicity 109, 111, 112

Animal models, Aspergillus fumigatus
infection
murine models 133, 134
overview 131–133
rabbit models 136
rat models 136

Antigens, Aspergillus fumigatus
cloning 47–49
diagnosis of aspergillosis
antibody detection 99
β-glucan detection 100
galactomannan detection 99
recombinant proteins in diagnosis 52
enzymes 72–74
identification 50–52, 71–76
polysaccharides 76, 77
proteases
dendoproteases 183, 184
exoproteases 184
expression of recombinant proteases in Pichia pastoris
alkaline protease 189
aspertic protease 189
metalloprotease 188, 189
propeptide requirement 187
Antigens, Aspergillus fumigatus, proteases (continued)
role in virulence 185, 186, 190
standardization of preparations 45, 47, 69
variation sources of extracts 70, 71
Western blot analysis 71
Aspergilloma
immunocompetent patients 28
overview 122
Asthma, Aspergillus antigens 24
Autonomously replicating plasmids,
Aspergillus fumigatus transfection 154

Bleeding
emergency surgery 116
hemorrhagic infarction in
immunocompromised patients 31, 32
prevention in well-circumscribed fungal masses 117

Calcium chloride transfection,
Aspergillus fumigatus 153
Central nervous system aspergillosis,
treatment 119, 120
Chitin synthase, Aspergillus
antifungal drug targeting 193, 203
classes 193, 194
cloning and gene structures from
A. nidulans and A. fumigatus 195–197
disruption studies
double disruption 201–203
single disruption 199–201
expression patterns of recombinant genes
in Escherichia coli 197, 198
functions in yeast 193, 194
Chronic disseminated aspergillosis,
presentation and treatment 30
Chronic necrotizing pulmonary aspergillosis,
overview 124, 131
Collagen, Aspergillus fumigatus adhesion 175, 176
Colonization, Aspergillus fumigatus
adhesion role 169–173
incidence in upper respiratory tract 121, 131

Conidia, Aspergillus fumigatus
adhesion to host cells, effects of culture
conditions 176–178
clearance 59
dose in pathogenesis 23
environmental distribution 22, 45, 46
germination 58
host response 60, 61
hydrophobicity and aeration 21
inhalation 21, 24, 167
metabolic activation 60
pigment
absence in nonpathogenic E. nidulans 210–213
biosynthesis 210, 212
complementation studies with pksP 209, 210
protection against immune effector cells 206, 207
virulence role 205, 206, 213
seasonal distribution 22
Corticosteroids, therapy as risk factor in
invasive aspergillosis 57, 61
Culture, Aspergillus fumigatus
conidia adhesion to host cells, effects of culture conditions 176–178
diagnostic culture
liquid samples 93–95
nonrespiratory samples 98, 99
overview 36
tissue samples 95, 97
media 10, 11
morphology and color 9
reference cultures 9, 10
Cutaneous aspergillosis
immunocompetent patients 25, 27
treatment 119
Cytokines
antifungal therapy 120
host defense in aspergillosis 62, 63
Defensins, antifungal defense 65
Differential fluorescence induction, virulence
factor analysis 161–163
1,8-Dihydroxynaphthalene-melanin
absence in nonpathogenic E. nidulans 210–213
biosynthesis 210, 212
complementation studies with pkp 209, 210
protection against immune effector cells 206, 207
virulence role 205, 206, 213
Disseminated aspergillosis, immunocompromised patients 34
Drosomycin, insect response to fungi 63, 64
Empyema, immunocompetent patients 28, 30
Endocarditis, surgical management 116
Endophthalmitis
immunocompetent patients 30
surgical management 116
Enzyme-linked immunosorbent assay
classification of Aspergillus 11
diagnosis of aspergillosis 36, 37, 77, 78, 97, 98
ER-30346, minimum inhibitory concentration 145
Extrinsic allergic alveolitis, clinical presentation 24, 123
Fibrinogen
adhesins on microorganisms
overview 167, 168
RGD-dependent recognition 175
sialic acid-dependent recognition 173, 175
colonization role with Aspergillus fumigatus adhesion 169–173
culture conditions, effects on conidia adhesion 176–178
structure 168
Fluconazole, aspergillosis treatment 38
Fresenius, J.B.G.W.
biography 3, 4
description of Aspergillus fumigatus 1–3
Fungal keratitis, immunocompetent patients 30
Granulocyte-macrophage colony-stimulating factor, aspergillosis treatment 38, 120
Hemorrhagic infarction, see Bleeding
Host response, aspergillosis 59–65
Human immunodeficiency virus, see
Acquired immunodeficiency syndrome
Hyperbaric oxygen, antifungal therapy 121
Ingestion, mycotoxins 23, 24
Inhalation, conidia 21, 24, 167
Insertional mutagenesis, Aspergillus fumigatus 155, 156
Intensive care, effects on aspergillosis outcome 121
Invasive aspergillosis
diagnosis
antibody detection 99, 106, 107
culture
liquid samples 93–95
nonrespiratory samples 98, 99
tissue samples 95, 97
enzyme-linked immunosorbent assay
36, 37, 77, 78, 97, 98
galactomannan detection 99
β-glucan detection 100, 107
microscopic examination of specimens 89
specimen types and diagnostic efficiency 88, 89
immunocompetent patients 28
immunocompromised patients 32, 34, 82
rare manifestations 119, 120
risk factors 57, 61, 106, 130, 182
strain fingerprinting 80, 81
treatment, see also Amphotericin B
antifungal testing, see Minimum inhibitory concentration
combination antifungals 115, 116
cytokines 120
failure 116
hyperbaric oxygen 121
Invasive aspergillosis, treatment (continued)
  intensive care 121
  itraconazole 38, 115
  novel therapeutics 124, 125, 139
  surgery indications 116–119
  white cell transfusion 120
  types of disease 131
In vivo expression technology, virulence factor analysis 161–163
Itraconazole
  aspergillosis treatment 38, 115
  combination therapy with other antifungals 115, 116
  minimum inhibitory concentration 144, 145
Knock-out, genes of Aspergillus fumigatus
  chitin synthase genes
    double disruption 201–203
    single disruption 199–201
    overview 156, 158, 159
Laminin
  adhesins on microorganisms
    overview 167–169
    sialic acid-dependent recognition 173, 175
  colonization role with Aspergillus fumigatus adhesion 169–172
  culture conditions, effects on conidia adhesion 176–178
  structure 168, 169
  Latex agglutination test, galactomannan detection 99
Macrophage, host response in aspergillosis
  60, 61, 65, 206, 207
Minimum inhibitory concentration, Aspergillus fumigatus antifungals
  amphotericin B 144, 145
  clinical relevance 140, 144, 145
  ER-30346 145
  itraconazole 144, 145
  nystatin 145
  SCH 56592 145
  solubilization of drugs 140
  tests
criterion for endpoints 143, 144, 146
  incubation conditions 143
  inoculum source, preparation, and size 142
  media formulations and pH 141, 142
  overview 140, 141
  voriconazole 145
Mouse models, Aspergillus fumigatus infection 133, 134
  Neutrophil, host response in aspergillosis 61, 62, 65
  Nystatin, minimum inhibitory concentration 145
Oral aspergillosis, treatment 119
Otitis externa
  Knock-out, genes of Aspergillus fumigatus
  immunocompetent patients 28
  overview 121
Phage display, cloning of Aspergillus antigens 48, 49, 52
Pleuritis, immunocompetent patients
  28, 30
Polymerase chain reaction
diagnosis of aspergillosis 37, 77, 78, 82, 98, 100, 108
  serum samples 100, 101
  strain fingerprinting 78–81
Pop-in/pop-out mutagenesis, Aspergillus fumigatus 159
Prophylaxis, aspergillosis 38, 78, 106
Proteases, Aspergillus fumigatus
  endoproteases 183, 184
  exoproteases 184
  expression of recombinant proteases in Pichia pastoris
  alkaline protease 189
  aspartic protease 189
  metalloprotease 188, 189
  propeptide requirement 187
  role in virulence 185, 186, 190
Protoplast transformation, Aspergillus fumigatus 153, 154
Pseudomembranous necrotizing bronchial aspergillosis, diagnosis 119
Rabbit models, *Aspergillus fumigatus* infection 136
Rat models, *Aspergillus fumigatus* infection 136
Rifampicin, aspergillosis treatment 115, 116
SCH 56592, minimum inhibitory concentration 145
Signature tagged mutagenesis, virulence factor analysis 161, 162
Sinusitis, *Aspergillus* allergic 124
immunocompetent patients 27
surgical management 118, 119
Spore, see Conidia
Staining, diagnosis of aspergillosis calcofluor fluorescent chitin stain 91
gram staining 91
overview 37
silver staining of sections 91
Strain fingerprinting invasive aspergillus 80, 81
rationale 78
typing methods 79, 80
Taxonomy, *Aspergillus* ascopore ornamentation 7
culture
media 10, 11
morphology and color 9
reference cultures 9, 10
DNA sequencing 12
enzyme analysis 11
immunoassay 11
metabolite analysis 11, 12
*Nosatopya* teleomorphs 15, 16
revision requirements 16, 17
section *Fumigati* 12–15
stabilization of nomenclature 8, 9
teleomorphs 5–7
workshops 5, 8
Thermotolerance, pathogenicity relationship in *Aspergillus fumigatus* 22
Tracheobronchitis
immunocompromised patients 31
overview 121
Transformation, *Aspergillus fumigatus*
automously replicating plasmids 154
calcium chloride transfection 153
chitin synthase genes, see Chitin synthase
electroporation limitations 154
functional complementation studies 155
fusion of genes 159, 160
insertional mutagenesis 155, 156
knock-out of genes 156, 158, 159
overview 149
pop-in/pop-out mutagenesis 159
protoplast transformation 153, 154
selectable markers
auxotrophic markers 151–153
dominant selectable markers 150, 151
virulence factor analysis
differential fluorescence induction 161–163
in vivo expression technology 161–163
signature tagged mutagenesis 161, 162
Virulence factors, *Aspergillus fumigatus*
conidia pigment
absence in nonpathogenic *E. nidulans* 210–213
biosynthesis 210, 212
complementation studies with *pksP* 209, 210
protection against immune effector cells 206, 207
virulence role 205, 206, 213
overview 58
proteases
endoproteases 183, 184
exoproteases 184
expression of recombinant proteases
in *Pichia pastoris* alkaline protease 189
aspartic protease 189
metalloprotease 188, 189
propeptide requirement 187
role in virulence 185, 186, 190
transformation analysis
differential fluorescence induction 161–163
in vivo expression technology 161–163
signature tagged mutagenesis 161, 162
Voriconazole, minimum inhibitory concentration 145